Tissue Regenix Group PLC PDMR Dealings (8254K)

TIDMTRX

RNS Number : 8254K

Tissue Regenix Group PLC

06 January 2021

Tissue Regenix Group plc

PDMR Dealings

Leeds, 6 January 2021 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group",) the regenerative medical devices company, has been notified that Trevor Phillips, independent Non-Executive Director of the Group, purchased 2,777,770 ordinary shares of 0.1p each in the Group ("Ordinary Shares") at a price of 0.54p per Ordinary Share for a total consideration of GBP14,999.96, on 6 January 2021.

Following this purchase, Mr. Phillips is beneficially interested in a total of 2,777,770 Ordinary Shares, representing approximately 0.04 per cent. of the Group's issued share capital.

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.

For more Information:

 
 Tissue Regenix Group plc 
  Caitlin Pearson Head of Communications       Tel: 0330 430 3052 
------------------------------------------  --------------------- 
 
 Stifel Nicolaus Europe Limited (Nominated   Tel: 0207 710 7600 
  Adviser and Broker) 
  Ben Maddison / Alex Price 
------------------------------------------  ---------------------

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies(R), a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.

 
  1   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Names                      Trevor Phillips 
     -------------------------  ---------------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------- 
 a)   Position/status            Independent Non-Executive Director 
     -------------------------  ---------------------------------------- 
 b)   Initial notification       Initial notification 
       /Amendment 
     -------------------------  ---------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------- 
 a)   Name                       Tissue Regenix Group plc 
     -------------------------  ---------------------------------------- 
 b)   LEI                         213800PNOD5UHQUFJI36 
     -------------------------  ---------------------------------------- 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------- 
 a)   Description                Ordinary Shares of 0.1p each 
       of the financial 
       instrument, 
       type of instrument 
     -------------------------  ---------------------------------------- 
 b)   Identification             GB00B5SGVL29 
       code 
     -------------------------  ---------------------------------------- 
 c)   Nature of the              Purchase of Ordinary Shares 
       transaction 
     -------------------------  ---------------------------------------- 
 d)   Price(s) and               Volume(s): 2,777,770 Ordinary Shares 
       volume(s)                  Price: 0. 54 pence per Ordinary Share 
     -------------------------  ---------------------------------------- 
 d)   Aggregated information     N/A 
       - Aggregated 
       volume 
       - Price 
     -------------------------  ---------------------------------------- 
 e)   Date of the                6 January 2021 
       transactions 
     -------------------------  ---------------------------------------- 
 f)   Place of the               AIM 
       transaction 
     -------------------------  ----------------------------------------

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSSFFIMEFSEIF

(END) Dow Jones Newswires

January 06, 2021 10:58 ET (15:58 GMT)

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2024 to Jun 2024